Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, June 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2025 (2025-06-30): -352.27%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-250.54%
RETURN ON EQUITY (ROE) AVG 3Y
-267.91%
RETURN ON EQUITY (ROE) AVG 5Y
-175.73%
RETURN ON EQUITY (ROE) AVG 10Y
-67.88%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.42B
Return on Equity (ROE)
N/A
TTM Avg
-250.54%
3Y Avg
-267.91%
5Y Avg
-175.73%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.44B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
Market Cap
$1.40B
Return on Equity (ROE)
-38.64%
TTM Avg
-84.50%
3Y Avg
-4452.86%
5Y Avg
-3001.92%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
Market Cap
$1.39B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.46B
Return on Equity (ROE)
-29.48%
TTM Avg
-5.20%
3Y Avg
-280.62%
5Y Avg
-280.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.42B | N/A | -250.54% | -267.91% | -175.73% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Certara, Inc. (CERT)vs › | $1.44B | -7.08% | -0.64% | -1.30% | -2.08% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -38.64% | -84.50% | -4452.86% | -3001.92% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | 41.79% | 41.79% | 41.79% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 23.70% | 9.74% | 8.98% | 11.20% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 9.00% | 8.29% | 7.90% | 8.39% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -29.48% | -5.20% | -280.62% | -280.62% |
| GH Research PLC (GHRS)vs › | $1.48B | -17.32% | -19.51% | -16.07% | -12.58% |
ROE
N/A
ROA
-46.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -352.27% |
| 2025-03-31 | -381.00% |
| 2024-12-31 | -222.95% |
| 2024-09-30 | -161.17% |
| 2024-06-30 | -135.31% |
| 2024-03-31 | -437.28% |
| 2023-12-31 | -220.26% |
| 2023-06-30 | -558.58% |
| 2023-03-31 | -326.14% |
| 2022-12-31 | -200.69% |
| 2022-09-30 | -144.63% |
| 2022-06-30 | -74.61% |
| 2022-03-31 | -59.04% |
| 2021-12-31 | -49.21% |
| 2021-09-30 | -38.08% |
| 2021-06-30 | -36.15% |
| 2021-03-31 | -19.31% |
| 2020-12-31 | -16.16% |
| 2020-09-30 | -38.48% |
| 2020-06-30 | -43.20% |
| 2020-03-31 | -69.77% |
| 2019-12-31 | -61.60% |
| 2019-09-30 | -54.55% |
| 2019-06-30 | -45.26% |
| 2019-03-31 | -36.61% |
| 2018-12-31 | -32.45% |
| 2018-09-30 | -28.90% |
| 2018-06-30 | -26.06% |
| 2018-03-31 | -28.13% |
| 2017-12-31 | -78.79% |
| 2017-09-30 | -79.79% |
| 2017-06-30 | -64.59% |
| 2017-03-31 | -53.51% |
| 2016-12-31 | -51.87% |
| 2016-09-30 | -50.41% |
| 2016-06-30 | -45.99% |
| 2016-03-31 | -36.13% |
| 2015-12-31 | -27.42% |
| 2015-09-30 | -18.58% |
| 2015-06-30 | -26.23% |
| 2015-03-31 | -19.80% |
| 2014-12-31 | -32.34% |
| 2014-09-30 | -27.28% |
| 2014-06-30 | -30.68% |
| 2014-03-31 | -25.32% |
| 2013-12-31 | -69.99% |
| 2013-09-30 | -46.90% |
